We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




New Implant to Help Patients Regenerate Their Own Heart Valves

By HospiMedica International staff writers
Posted on 12 Feb 2025

Each year, millions of people worldwide are diagnosed with heart valve disease, yet there is no effective long-term treatment for the condition. More...

When a person’s heart valve is severely damaged due to a birth defect, lifestyle factors, or aging, blood flow is disrupted. If left untreated, this can lead to life-threatening complications. Valve replacement and repair are currently the only ways to manage severe valvular heart disease, but both often require repeated surgeries that are costly, disruptive, and carry significant risks. Most replacement valves are made from animal tissue and last between 10 and 15 years before needing replacement. For pediatric patients, available solutions are extremely limited and may require multiple reinterventions. Now, researchers have developed a 3D-printed heart valve made from bioresorbable materials, designed to match an individual patient’s specific anatomy. Once implanted, the valve will gradually be absorbed by the body and replaced with new tissue, which will take over the function the device originally performed.

One of the main challenges in pediatrics is that children grow, which causes their heart valves to change size over time. As a result, children often need multiple surgeries to repair or replace their heart valves as they grow. The groundbreaking technology developed by researchers at Georgia Institute of Technology (Atlanta, GA, USA) could potentially allow patients to grow new valve tissue, eliminating the need for multiple valve replacements in the future. Although 3D-printed heart valves and bioresorbable materials have been used for implants before, this is the first time both technologies have been combined to create a single device made from a resorbable, shape-memory material. The team’s initial research involved selecting the appropriate material and testing various prototypes. The resulting heart valve is 3D-printed from a biocompatible material known as poly(glycerol dodecanedioate).

The valve has shape-memory properties, enabling it to be folded and delivered via a catheter, instead of requiring open-heart surgery. Once implanted and warmed to body temperature, the device will unfold into its original shape. The material then signals the body to create its own new tissue to replace the device, which will be completely absorbed within a few months. The team is currently evaluating the physical durability of the heart valve using both computational models and benchtop studies. Their laboratory is equipped with a heart simulation setup that mimics the physiological conditions of a real heart, including the pressure and flow conditions specific to an individual patient. An additional machine tests the valve’s mechanical durability by subjecting it to millions of heart cycles in a short period.

The researchers note that creating a material capable of performing the rigorous functions of a heart valve while encouraging the development of new tissue is an enormous challenge. Additionally, new medical devices face a long journey from the laboratory to clinical use, with several critical milestones to achieve along the way. The researchers hope that their technology will revolutionize heart valve treatment and usher in a new era of tissue-engineered devices. They also point out that pediatric implants are developed less frequently than adult ones, due to the rarity of childhood diseases and the high manufacturing costs. The team believes that combining bioresorbable materials with 3D printing could be the key to developing better devices for pediatric patients.

“This technology is very different from most existing heart valves, and we believe it represents a paradigm shift,” said researcher Lakshmi Prasad Dasi, the Rozelle Vanda Wesley Professor in BME. “We are moving away from using animal tissue devices that don’t last and aren’t sustainable, and into a new era where a heart valve can regenerate inside the patient.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Dual Chamber Warming Cabinet
D-Series
New
Diagnostic Ultrasound System
DC-80A
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.